2020年12月15日
SOMERSET, N.J., December 15, 2020 – Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, will participate virtually in the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021. Ying Huang, PhD, Chief Executive Officer and Chief Financial Officer of Legend Biotech, will present company updates on Wednesday, January 13, 2021 at 4:30 pm ET.
The webcast will be available to investors and other interested parties in the Events & Presentation section under Investors on Legend Biotech’s website at
https://investors.legendbiotech.com/events-and-presentations. A webcast replay will be available approximately 24-hrs after the live webcast.
About Legend Biotech
Legend Biotech is a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Our team of over 800 employees across the United States, China and Europe, along with our differentiated technology, global development, and manufacturing strategies and expertise, provide us with the strong potential to discover, develop, and manufacture cutting -edge cell therapies for patients in need. We are engaged in a strategic collaboration to develop and commercialize our lead product candidate, ciltacabtagene autoleucel, an investigational BCMA targeted CAR-T cell therapy for patients with multiple myeloma. This candidate is currently being studied in registrational clinical trials. To learn more about Legend Biotech, visit us on LinkedIn, or on Twitter @LegendBiotech or at www.legendbiotech.com.
For Media and Investor Relations inquiries, please contact:
Jessie Yeung, Head of Corporate Finance and Investor Relations, Legend Biotech
jessie.yeung@legendbiotech.com or investor@legendbiotech.com
Surabhi Verma, Manager of Investor Relations and Corporate Communications, Legend Biotech
Surabhi.verma@legendbiotech.com or media@legendbiotech.com
傳奇生物公布2024年第四季度和全年業(yè)績及近期亮點
2025年3月11日
傳奇生物公布2024年第三季度業(yè)績及近期亮點
2024年11月12日
精彩預告 | 傳奇生物CARTITUDE-4最新研究成果即將亮相2024ASH年會
2024年11月5日
傳奇生物任命Alan Bash為CARVYKTI?總裁
2024年11月4日
傳奇生物在費城新建先進的細胞治療研發(fā)設施
2024年10月3日